For decades, confirming Alzheimer’s disease required a spinal tap or a PET scan that few patients ever received. In 2025 the FDA cleared the first plasma p-tau217 blood test, and 2026 is the year it begins reshaping who gets diagnosed, when, and what they can do about it.
A landmark Science study reveals that genes control over 50 percent of lifespan variation. Meanwhile, the PROACT trial uses polygenic risk scores to find hidden heart disease, and whole genome sequencing is entering routine clinical care. Precision medicine in 2026 is no longer a promise. It is arriving.
A new generation of AI systems does not just assist scientists; it organizes itself into research teams, designs experiments, debates hypotheses, and identifies drug candidates at speeds no human laboratory can match. The implications for longevity medicine are staggering. For most of pharmaceutical history, drug discovery worked like this: a scientist formed a hypothesis, designed…
A foundation model company just paid $400 million in stock for a team of fewer than 10 people. The implications for drug discovery, precision medicine, and the entire healthcare AI landscape are enormous. On April 3, 2026, Anthropic confirmed the acquisition of Coefficient Bio, a stealth biotech AI startup, in an all-stock transaction valued at…
A convergence of cfDNA methylation analysis, multi-omics integration, and artificial intelligence is transforming cancer screening. From the PATHFINDER 2 trial showing a seven-fold increase in cancer detection to the PROMISE study achieving 79 percent sensitivity across nine cancer types, liquid biopsy is moving from laboratory concept to clinical reality. Here is what the science means for your health.
ARPA-H’s $144 million PROSPR program is testing rapamycin, semaglutide, and dapagliflozin in 726 healthy older adults, funding a first-in-humans trial of a retrotransposon-silencing HIV drug, and building a validated biological healthspan score. It is the largest federal commitment to extending human healthspan ever assembled.
David Sinclair helped make longevity science impossible to ignore. He also became one of its most contested public figures. Part II examines the criticism, contradictory evidence, and scientific arguments that define the battle over his legacy and the future of aging research.
David Sinclair helped move aging research from the scientific margins into mainstream conversation. Through his Harvard lab, his work on sirtuins, NAD+ biology, epigenetic reprogramming, and his public role as a translator of longevity science, he helped make aging a serious biomedical frontier.
Harvard researcher Marinka Zitnik is building AI systems designed to uncover hidden treatments for rare and neglected diseases. Her TxGNN work points toward a future where drug repurposing becomes more systematic, more transparent, and more useful for patients medicine has historically overlooked.
Every Cure is a nonprofit using AI and drug repurposing to uncover treatments hidden inside existing medicines. Founded by physician-scientist David Fajgenbaum after a repurposed drug saved his own life, the organization is building a new model for healthcare discovery.
Zach RobertsSign up for personalized wellness coaching and the Daily Discovery Newsletter.